BoNT-A injections improve urothelial function in patients with IC/BPS by decreasing P2X3 and TRPV1 receptor expression in the urothelium, which is a likely mechanism reducing pain in patients with IC/BPS [60]. The gene discussed is P2RX3; the disease is Bartsocas-Papas syndrome 1.